Investor Relations May 13, 2025 Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data Read More
Investor Relations May 6, 2025 Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering Read More
Investor Relations May 5, 2025 Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock Read More
Investor Relations May 1, 2025 Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback Read More
Investor Relations April 24, 2025 Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia Read More
Investor Relations April 23, 2025 Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management Read More
